electroCore to acquire NeuroMetrix
Acquisition Announcement: electroCore (ECOR) has agreed to acquire NeuroMetrix (NURO) and its Quell platform, excluding the DPNCheck technology, with the deal expected to close by the end of Q1 2025, pending shareholder approval and regulatory filings.
Financial Details: NeuroMetrix shareholders will receive cash at closing and a contingent value right linked to future proceeds from the DPNCheck divestiture and royalties on Quell product sales, while the transaction is not anticipated to significantly impact electroCore's cash or equity.
Get Free Real-Time Notifications for Any Stock
Analyst Views on ECOR
About ECOR
About the author
electroCore (ECOR) Projects 2025 Revenue Between $31.8M and $32M
- Revenue Guidance: electroCore anticipates 2025 revenue between $31.8M and $32M, slightly below the consensus of $31.81M, indicating a cautious outlook on future growth.
- Q4 Growth Projection: The company expects Q4 2025 revenue to be between $9M and $9.2M, representing approximately 30% growth over Q4 2024, suggesting strengthening competitive positioning in the market.
- Cash Position: By the end of 2025, electroCore expects to have approximately $11.6M in cash, down from about $13.2M as of September 30, 2025, reflecting pressure from expansion and investment expenditures.
- Market Reaction: ECOR shares fell 0.62% in premarket trading to $7.0957, indicating investor caution regarding the revenue outlook.
ElectroCore Increases 2025 Revenue Forecast to $32.5M Amid Enhanced Investments and Strategic Growth
Management Strategy: Dr. Thomas Errico highlighted a strategic shift towards growth through targeted investments, acquisitions, and partnerships, focusing on expanding product offerings and enhancing shareholder value while deferring profitability.
Financial Performance: The company reported a record revenue of $8.7 million for Q3 2025, a 33% increase year-over-year, with strong gross margins of 86%, driven by prescription device sales and growth in the VA hospital system.
Outlook and Guidance: CEO Daniel Goldberger raised the full-year revenue guidance to $31.5 million to $32.5 million, projecting a cash balance of approximately $10.5 million by year-end and aiming for positive adjusted EBITDA in the second half of 2026.
Risks and Challenges: Management acknowledged ongoing litigation and the impact of macroeconomic factors on revenue, emphasizing that continued investments in sales and R&D may delay near-term profitability but are essential for long-term growth.
